Standards and monitoring treatment

Haemophilia

Volumn 18, Issue SUPPL.4, 2012, Pages 61-65

  Barrowcliffe, T W ^a   Hubbard, A R ^a   Kitchen, S ^b  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Clotting factors; International; Standard

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR CONCENTRATE; FIBRINOGEN; PEGYLATED BLOOD CLOTTING FACTOR 8; PEGYLATED BLOOD CLOTTING FACTOR 9; PROTEIN C; PROTEIN S; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING; CALIBRATION; DIAGNOSTIC ACCURACY; DRUG FORMULATION; DRUG LABELING; DRUG POTENCY; HEMOPHILIA; HUMAN; INTERNATIONAL STANDARD UNIT; LABORATORY TEST; MONITORING; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REPRODUCIBILITY; STANDARD; STANDARDIZATION; WORLD HEALTH ORGANIZATION;

BLOOD COAGULATION DISORDERS; BLOOD COAGULATION TESTS; COAGULANTS; FACTOR VIII; HUMANS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS;

EID: 84862846429     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02831.x     Document Type: Article

References (35)

1. Jeffcoate SL. From insulin to amylin: 75 years of biological standardisation in endocrinology. Dev Biol Stand 1999; 100: 39-47.
2. Brozovic M, Bangham DR. Standards for heparin. Adv Exp Med Biol 1975; 52: 163-79.
3. Biggs R, Bangham DR. Standardisation of the one-stage prothrombin time test for the control of anticoagulant therapy. The availability and use of thromboplastin reference preparations. Thromb Diath Haemorrh 1971; 26: 203-4.
4. Bangham DR, Biggs R, Brozovic M, Denson KWE, Skegg JL. A biological standard for measurement of blood coagulation factor VIII activity. Bull World Health Organ 1971; 45: 337-51.
5. Barrowcliffe TW, Hubbard AR. International Standards in Hemostasis. In: Preston FE, Kitchen S, Olson JD eds. Quality Control in Hemostasis and Thrombosis. Wiley-Blackwell, 2012. [Epub ahead of print].
6. Campbell PJ. International biological standards and reference preparations. I. Preparation and presentation of materials to serve as standards and reference preparations. J Biol Stand 1974; 2: 249-58.
7. Campbell PJ. International biological standards and reference preparations. II. Procedures used for the production of biological standards and reference preparations. J Biol Stand 1974; 2: 259-67.
8. Kirkwood TBL. Predicting the stability of biological standards and products. Biometrics 1977; 33: 736-42.
9. Kirkwood TBL, Barrowcliffe TW. Discrepancy between 1-stage and 2-stage assay for Factor VIII:C. Br J Haematol 1978; 40: 333-8.
10. Barrowcliffe TW, Tydeman MS, Kirkwood TBL, Thomas DP. Standardisation of Factor VIII. III: Establishment of a stable reference plasma for Factor VIII-related activities. Thromb Haemost 1983; 50: 690-6.
11. th International Standard for Blood Coagulation Factor VIII and von Willebrand factor in Plasma (07/316). J Thromb Haemost 2011; 9: 2100-2.
12. Brozovic M, Bangham DR. Study of a proposed International Standard for Factor IX. Thromb Haemost 1976; 35: 222-36.
13. Barrowcliffe TW. Standardisation of Factors II, VII, IX, and X in plasma and concentrates. Thromb Haemost 1987; 59: 334.
14. Hubbard AR, Weller LJ, Bevan SA. A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates. Br J Haematol 2002; 117: 247-8.
15. Farrugia A. Potency assessment of the new generation of coagulation factor concentrates - time for a new paradigm? Thromb Haemost 2003; 90: 968-70.
16. Pipe SW. Hemophilia: new protein therapeutics. Hematology Am Soc Hematol Educ Program. 2010; 2010: 203-9.
17. Schaub RG. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Biochem Pharmacol 2011; 82: 91-8.
18. Peters RT, Low SC, Kamphaus GD et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010; 115: 2057-64.
19. Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 2009; 102: 634-44.
20. Buyue Y, Liu T, Reidy T et al. A novel single chain recombinant factor VIII Fc fusion protein is active in vitro and fully efficacious in an in vivo Hem A mouse bleeding model. Blood 2011; 118: 1192.
21. Smolen J, Landewé RB, Mease P et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804.
22. Mei B, Pan C, Jiang H et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-9.
23. Leong L, Evans V, Ramsey P, Tang L, Murphy JE, Apeler H et al. Evaluation of methods for potency testing of pegylated FVIII (PEG-FVIII, BAY 94-9027). J Thromb Haemost 2011; 9 (Suppl. 2): Poster P-TU-223.
24. Østergaard H, Bjelke JR, Hansen L et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 2011; 118: 2333-41.
25. Christiansen MLS, Balling KW, Persson E et al. Functional characteristics of N8, a new recombinant FVIII. Haemophilia 2010; 16: 878-87.
26. Pahl S, Schwaab R, Oldenburg J, Herbiniaux U, Aburubaiha Z. Characterisation of natural FVIII variants of the B-domain regarding their biological activity. Haemophilia 2010; 16(Suppl. 4): 95.
27. Barrow RT, Lollar P. Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII. J Thromb Haemost 2006; 4: 2223-9.
28. Weimer T, Wormsbächer W, Kronthaler U, Lang W, Liebing U, Schulte S. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost 2008; 99: 659-67.
29. Mikaelsson M, Oswaldsson U, Jankowski MA. Measurement of factor VIII activity of B-domain-deleted recombinant factor VIII. Semin Haematol 2001; 38(Suppl. 4): 13-23.
30. Viuff D, Barrowcliffe TW, Saugstrup T, Ezban M, Lillicrap D. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia 2011; 17: 695-702.
31. Lee CA, Owens D, Bray G et al. Pharmacokinetics of recombinant factor VIII (Recombinate) using one-stage clotting and chromogenic factor VIII assay. Thromb Haemost 1999; 82: 1644-7.
32. Morton A, Middleton S, Hubbard AR, Barrowcliffe TW. Problems associated with the comparison of porcine and human factor VIII. Thromb Haemost 1985; 54: 20.
33. Hubbard AR, Weller LJ, Bevan SA. Activation profiles of FVIII in concentrates reflect one-stage/chromogenic potency discrepancies. Br J Haematol 2002; 117: 957-60.
34. Raut S, Heath AB, Barrowcliffe TW. A collaborative study to establish the 6th International Standard for factor VIII concentrate. Thromb Haemost 2001; 85: 1071-8.
35. Lee C, Barrowcliffe TW, Bray G et al. Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M. Thromb Haemost 1996; 76: 950-6.